MeetBridge is a B2B meeting marketplace where companies find and book qualified 30-minute video meetings with relevant business partners. Companies are matched by industry, geography, business intentions, and availability.

How does match scoring work?

Match scores evaluate compatibility across four dimensions: industry alignment, geographic focus overlap, mutual intent compatibility, and availability overlap. The result is a single percentage score showing how likely a meeting would be productive.

Is MeetBridge free to use?

Yes, MeetBridge offers a free plan with 22 points per month. New users get a 90-day free trial with 500 points (Pro-level access). The Pro plan costs $100/month for unlimited meetings and 500 points.

What types of businesses use MeetBridge?

MeetBridge serves brands, affiliates, agencies, publishers, SaaS providers, consultancies, and networks. The first vertical focuses on affiliate-brand partnerships, helping companies find qualified partners for performance marketing collaborations.

How do video meetings work on MeetBridge?

MeetBridge uses WebRTC peer-to-peer video calling built directly into the platform. Once both parties approve a meeting, they can join the 30-minute video call at the scheduled time without downloading any software.

How much does a meeting cost in points?

Searching for partners costs 2 points. Sending a meeting request costs 10 points. Approving a meeting costs 5 points. Both sides invest points, which ensures quality interactions and prevents spam.

Can I try MeetBridge before paying?

Absolutely. Every new account gets a 90-day free trial with 500 points per month — that's full Pro-level access with no credit card required.

What happens after a meeting?

After each meeting, both parties can optionally share their contact details (email and phone) and schedule follow-up meetings directly through the platform.

How is MeetBridge different from LinkedIn?

MeetBridge is purpose-built for qualified business meetings. Instead of generic connections and cold DMs, every interaction is intent-matched, scored for relevance, and gated by mutual agreement. You only meet partners who are genuinely relevant to your business.

Is my data safe on MeetBridge?

Yes. Passwords are encrypted, sessions are secured, and all connections use HTTPS. Contact details are only shared after you explicitly opt in following a completed meeting.

An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes

SaaS Provider in Finance · Global · Unclaimed Profile

About An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes

EU Funded (H2020) Research Project. With a focus on global markets across multiple continents, An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes is a saas provider in financial services and fintech, including payments, banking, insurance, lending, and financial technology. MeetBridge enables qualified businesses to connect with An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes for B2B meetings and partnership discussions.

An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes is a saas provider operating in the financial services and fintech industry, including payments, banking, insurance, lending, and financial technology. With a global focus, An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes serves clients and partners across multiple regions and markets.

As a saas provider in the finance space, An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes is positioned to work with companies looking for Financial planning and analysis, Payment processing, Risk management and related capabilities. Once this profile is claimed by a company representative, businesses will be able to request meetings through MeetBridge.

Company Details

Company Name	An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes
Business Type	SaaS Provider
Industry	Finance
Service Area	Global
Profile Status	Unclaimed — Sourced from public data
Website	https://repo-trial.eu/

Finance Services and Capabilities

Companies like An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes in the finance industry typically provide the following types of services:

Financial planning and analysis
Payment processing
Risk management
Regulatory compliance
Accounting and bookkeeping
Invoice and billing
Treasury management
Financial reporting
Tax preparation
Audit services

The specific services offered by An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes may vary. Claim this profile to add your specific services and start connecting with B2B partners.

Is this your company?

This profile for An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes was created from publicly available information and hasn't been claimed yet. If you represent An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes, claiming this profile allows you to:

Manage and update your company information
Receive and respond to B2B meeting requests
Connect with relevant partners matched by industry and intent
Access a free 90-day trial with full platform features

Claim An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes on MeetBridge

Frequently Asked Questions about An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes

What does An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes do?

What value does An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes bring as a business partner?

As a saas provider in the Finance space, An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes brings expertise and focus in the financial services and fintech industry, including payments, banking, insurance, lending, and financial technology. With a global reach, An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes can support partners across multiple markets.

What topics can I discuss with An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes in a meeting?

A 30-minute meeting with An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes on MeetBridge is a good opportunity to explore transaction volumes, compliance certifications, payment infrastructure, and the mutual fit for a partnership. Both parties can review profiles and intentions before the meeting to ensure it's productive.

What services does An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes offer?

An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes is active in the financial services and fintech industry, including payments, banking, insurance, lending, and financial technology, which typically encompasses financial planning, payment processing, risk management, regulatory compliance, accounting. The specific services An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes offers can be discussed in a direct meeting — request one through MeetBridge.

Is An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes verified on MeetBridge?

An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes's profile has not been claimed yet. The information shown is sourced from publicly available data. If you represent An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes, you can claim this profile to verify and manage it.

How can I connect with An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes for a partnership?

An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes's profile on MeetBridge has not yet been claimed. Once a representative claims this profile, you'll be able to request B2B meetings directly through the platform.

What markets does An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes serve?

An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes focuses on worldwide, serving clients and partners across multiple continents and markets. Through MeetBridge, An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes can connect with B2B partners both within their primary market and internationally.

What types of companies does An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes work with?

As a saas provider in the Finance industry, An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes typically works with companies across the finance space. Through MeetBridge, An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes can be matched with the most relevant partners.

What industry does An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes operate in?

Similar Finance Companies on MeetBridge

Explore other finance companies in the MeetBridge directory that may be relevant for B2B partnerships:

Wealthfront — Brand, Global
Employers Holdings Inc — Brand, Global
T. Rowe Price — Brand, Global
Zions Bank — Brand, Global
CBL Properties — Brand, Global
Esure — Brand, Global
Liu Chong Hing Investment Ltd. — Brand, Global
Utkarsh Small Finance Bank — Brand, Global

Browse all companies in the MeetBridge directory

How MeetBridge Works

MeetBridge is a B2B meeting marketplace that helps companies discover and connect with relevant business partners through qualified 30-minute video meetings.

Create your company profile — Sign up for free, describe your business, industry, and what you're looking for in B2B partnerships.
Discover and match with partners — Our matching system scores companies by industry, geography, and mutual intent so you find the right fit fast.
Book a 30-minute video meeting — Pick an available time slot, explain why it's a good fit, and connect via built-in video call — no external tools needed.

MeetBridge offers a free 90-day trial with 500 points per month. After the trial, companies can continue with a free plan or upgrade to Pro ($100/month) for expanded access.